AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17919250 — intervention group
Group type: COMPARATOR
Intervention: Conventional flapped procedure
Number of subjects: 12
Study 16137016 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy plus endoscopic variceal ligation (EVL)
Number of subjects: 51
Study 16137016 — intervention group
Group type: COMPARATOR
Intervention: Pericardial devascularization (Control)
Number of subjects: 51
Study 16137016 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy plus EVL
Number of subjects: 51
Study 11317660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (AERx iDMS) at dosages of 0.3, 0.6, 1.2, and 1.8 U/kg body weight
Number of subjects: 18
Study 11317660 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (0.12 U/kg body weight)
Number of subjects: 18
Study 11317660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (AERx iDMS)
Number of subjects: 18
Study 9225173 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid
Number of subjects: 0
Study 9225173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8236144 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120, 240, or 360 mg/day)
Number of subjects: 25
Study 8236144 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81 mg/day)
Number of subjects: 25
Study 8236144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Diltiazem (81 mg/day + diltiazem)
Number of subjects: 25
Study 8236144 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 25
Study 8236144 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 25
Study 3828918 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood collected in the Sorensen ATS Autotransfusion Receptal unit
Number of subjects: 0
Study 3828918 — intervention group
Group type: COMPARATOR
Intervention: Arterial autologous blood
Number of subjects: 0
Study 31149881 — intervention group
Group type: EXPERIMENTAL
Intervention: tiletamine-zolazepam
Number of subjects: 6
Study 31149881 — intervention group
Group type: EXPERIMENTAL
Intervention: alfaxalone
Number of subjects: 6
Study 31149881 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 6
Study 31149881 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine-diazepam
Number of subjects: 6
Study 28793958 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200 mg)
Number of subjects: 20
Study 28793958 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of amisulpride
Number of subjects: 20
Study 28793958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 25713002 — intervention group
Group type: EXPERIMENTAL
Intervention: gammaCore (noninvasive vagus nerve stimulator)
Number of subjects: 19
Study 23622906 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFreedom drug-coated stent
Number of subjects: 2456
Study 23622906 — intervention group
Group type: COMPARATOR
Intervention: Gazelle bare metal stent
Number of subjects: 2456
Study 20728093 — intervention group
Group type: EXPERIMENTAL
Intervention: 4× above the seizure threshold (ST)
Number of subjects: 41
Study 20728093 — intervention group
Group type: EXPERIMENTAL
Intervention: 7× above the seizure threshold (ST)
Number of subjects: 41
Study 20728093 — intervention group
Group type: EXPERIMENTAL
Intervention: 10× above the seizure threshold (ST)
Number of subjects: 41
Study 20728093 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intensity groups
Number of subjects: 41
Study 20728093 — intervention group
Group type: EXPERIMENTAL
Intervention: 4×, 7×, and 10× above ST
Number of subjects: 41
Study 16401468 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg)
Number of subjects: 50
Study 16401468 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 50
Study 16401468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15364856 — intervention group
Group type: EXPERIMENTAL
Intervention: FloWatch-PAB
Number of subjects: 13
Study 11391165 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-mg amprenavir (APV) combined with 800-mg indinavir (IDV)
Number of subjects: 48
Study 11391165 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-mg amprenavir (APV) combined with 750-mg nelfinavir (NFV)
Number of subjects: 48
Study 11391165 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-mg amprenavir (APV) combined with 800-mg saquinavir-Soft Gel Capsule (SGV-SGC)
Number of subjects: 48
Study 11391165 — intervention group
Group type: EXPERIMENTAL
Intervention: APV given alone for 3 weeks and then with 150-mg lamivudine (3TC) and 300-mg zidovudine (ZDV)
Number of subjects: 48
Study 10087435 — intervention group
Group type: EXPERIMENTAL
Intervention: SK+heparin
Number of subjects: 90
Study 10087435 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA+heparin
Number of subjects: 90
Study 10087435 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 90
Study 10087435 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 90
Study 10087435 — intervention group
Group type: EXPERIMENTAL
Intervention: SK and rt-PA
Number of subjects: 90
Study 10087435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous heparin
Number of subjects: 90
Study 8149437 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable intracoronary stenting in patients with stable angina (n = 57)
Number of subjects: 105
Study 8149437 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable intracoronary stenting in patients with unstable angina (n = 48)
Number of subjects: 105
Study 8149437 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable intracoronary stenting
Number of subjects: 105
Study 3408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 0
Study 3408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (Niopam)
Number of subjects: 0
Study 3408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque)
Number of subjects: 0
Study 3408846 — intervention group
Group type: COMPARATOR
Intervention: Control (other contrast media)
Number of subjects: 0
Study 31678507 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Cesarean Delivery
Number of subjects: 0
Study 31678507 — intervention group
Group type: COMPARATOR
Intervention: Planned Vaginal Delivery
Number of subjects: 0
Study 31678507 — intervention group
Group type: COMPARATOR
Intervention: Previous Cesarean Delivery
Number of subjects: 0
Study 29278871 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dysphagia therapy (TDT) + surface neuromuscular electrical stimulation (sNMES) in treatment group A (TGA)
Number of subjects: 30
Study 29278871 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dysphagia therapy (TDT) + surface neuromuscular electrical stimulation (sNMES) in treatment group B (TGB)
Number of subjects: 30
Study 29278871 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional dysphagia therapy only)
Number of subjects: 30
Study 27627126 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson relaxation technique applied for five days
Number of subjects: 50
Study 27627126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 25524960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for nurses
Number of subjects: 35
Study 23254482 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Cog power meter
Number of subjects: 0
Study 23254482 — intervention group
Group type: COMPARATOR
Intervention: SRM and PowerTap devices
Number of subjects: 0
Study 21483400 — intervention group
Group type: EXPERIMENTAL
Intervention: Digerfast (medical device)
Number of subjects: 36
Study 21483400 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (Peridon)
Number of subjects: 36
Study 18727842 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/24-h nicotine patch
Number of subjects: 346
Study 18727842 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/16-h nicotine patch
Number of subjects: 346
Study 18727842 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 346
Study 16505657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg/kg/min)
Number of subjects: 100
Study 16505657 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (2 microg/kg/min)
Number of subjects: 100
Study 14633745 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea
Number of subjects: 14
Study 14633745 — intervention group
Group type: COMPARATOR
Intervention: Control (assisted spontaneous ventilation)
Number of subjects: 14
Study 11104115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention counseling (7 sessions)
Number of subjects: 118
Study 11104115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention counseling (3 sessions)
Number of subjects: 118
Study 11104115 — intervention group
Group type: COMPARATOR
Intervention: Minimal advice (Control group)
Number of subjects: 118
Study 11104115 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 118
Study 8761582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day Quinimax treatment (25 mg/kg daily in 3 doses)
Number of subjects: 72
Study 8761582 — intervention group
Group type: COMPARATOR
Intervention: 7-day Quinimax treatment (25 mg/kg daily in 3 doses)
Number of subjects: 72
Study 8761582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day Quinimax treatment
Number of subjects: 72
Study 2328746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg b.d. for one week
Number of subjects: 30
Study 2328746 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. for one week
Number of subjects: 30
Study 7016264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate with epinephrine
Number of subjects: 100
Study 7016264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate without epinephrine
Number of subjects: 100
Study 7016264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride with epinephrine
Number of subjects: 100
Study 7016264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride without epinephrine
Number of subjects: 100
Study 7016264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate
Number of subjects: 100
Study 7016264 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride
Number of subjects: 100
Study 30561570 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans of lymph nodes
Number of subjects: 426
Study 28652290 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg for 2 weeks, then 60 mg for 4 weeks)
Number of subjects: 81
Study 28652290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 26385214 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely obese patients (BMI ≥ 40)
Number of subjects: 3754
Study 26385214 — intervention group
Group type: COMPARATOR
Intervention: Moderately obese, slightly obese, and overweight patients
Number of subjects: 3754
Study 26385214 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer patients
Number of subjects: 3754
Study 26385214 — intervention group
Group type: COMPARATOR
Intervention: Other tumor subtypes
Number of subjects: 3754
Study 22698840 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw relaxation for 20 min before dressing changes
Number of subjects: 100
Study 22698840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no jaw relaxation)
Number of subjects: 100
Study 21651805 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week exercise intervention (the HOPE programme)
Number of subjects: 0
Study 21651805 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19188077 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming to a nasopharyngeal temperature of 33 degrees C (Group 1)
Number of subjects: 80
Study 19188077 — intervention group
Group type: COMPARATOR
Intervention: Rewarming to a nasopharyngeal temperature of 37 degrees C (Group 2)
Number of subjects: 80
Study 16780624 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) and dynamic bracing
Number of subjects: 24
Study 16780624 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) alone
Number of subjects: 24
Study 16780624 — intervention group
Group type: COMPARATOR
Intervention: Dynamic bracing alone
Number of subjects: 24
Study 15113316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once-daily for 5-14 days
Number of subjects: 0
Study 15113316 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice-daily for 5-14 days
Number of subjects: 0
Study 11205428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarette
Number of subjects: 40
Study 11205428 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 40
Study 9505889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal stent for patients with an inoperable tumour smaller than 30 mm
Number of subjects: 101
Study 9505889 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stent for patients with a tumour greater than 30 mm
Number of subjects: 101
Study 8174528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (200 micrograms added to St. Thomas' cardioplegia)
Number of subjects: 24
Study 8174528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (added to St. Thomas' cardioplegia)
Number of subjects: 24
Study 3286129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 105
Study 3286129 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 105
Study 30449852 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue artificial hydration and nutrition for terminal stage patients who could no longer communicate
Number of subjects: 500
Study 30449852 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue artificial hydration and nutrition for bedridden patients with tendency to self-remove tubes
Number of subjects: 500
Study 30449852 — intervention group
Group type: COMPARATOR
Intervention: Physicians working in hospitals
Number of subjects: 500
Study 30449852 — intervention group
Group type: COMPARATOR
Intervention: Physicians working in private clinics
Number of subjects: 500
Study 27597731 — intervention group
Group type: EXPERIMENTAL
Intervention: Target range of 85%-89% oxygen saturation
Number of subjects: 0
Study 27597731 — intervention group
Group type: COMPARATOR
Intervention: Target range of 91%-95% oxygen saturation
Number of subjects: 0
Study 25322274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg Resveratrol (RSV(high))
Number of subjects: 74
Study 25322274 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Resveratrol (RSV(low))
Number of subjects: 74
Study 25322274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23128667 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-led exercise
Number of subjects: 314
Study 23128667 — intervention group
Group type: EXPERIMENTAL
Intervention: FI-led exercise
Number of subjects: 314
Study 23128667 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 314
Study 23128667 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 314
Study 20653352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing follow‐up by the pharmacist (follow‐up group)
Number of subjects: 176
Study 20653352 — intervention group
Group type: COMPARATOR
Intervention: Return to usual care (single‐contact group)
Number of subjects: 176
Study 18977721 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 228
Study 18977721 — intervention group
Group type: COMPARATOR
Intervention: nevirapine (NVP)
Number of subjects: 228
Study 17283932 — intervention group
Group type: EXPERIMENTAL
Intervention: Color transients
Number of subjects: 0
Study 17283932 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance transients
Number of subjects: 0
Study 17283932 — intervention group
Group type: COMPARATOR
Intervention: No-transient condition
Number of subjects: 0
Study 12945072 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy smoke extraction system (group 2)
Number of subjects: 30
Study 12945072 — intervention group
Group type: COMPARATOR
Intervention: Standard diathermy equipment (group 1)
Number of subjects: 30
Study 10742365 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 6
Study 10742365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8771642 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support intervention during pregnancy (four to six home visits providing emotional support, counseling, and strengthening of the woman's social network)
Number of subjects: 2235
Study 8771642 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support intervention during pregnancy
Number of subjects: 2235
Study 1589237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1200 mg in effervescent solution)
Number of subjects: 60
Study 1589237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically tasting solution without aspirin)
Number of subjects: 60
Study 1589237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and Placebo
Number of subjects: 60
Study 3755052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg oral dose)
Number of subjects: 6
Study 3755052 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (four times a day for 2 days prior to cimetidine ingestion)
Number of subjects: 6
Study 31514562 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration
Number of subjects: 74
Study 31514562 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques (control)
Number of subjects: 74
Study 29616454 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion
Number of subjects: 81
Study 29616454 — intervention group
Group type: COMPARATOR
Intervention: Social inclusion
Number of subjects: 81
Study 27085322 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + OM exercises
Number of subjects: 82
Study 27085322 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy (OMT) + OM exercises
Number of subjects: 82
Study 27085322 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT placebo + OM exercises
Number of subjects: 82
Study 27085322 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 82
Study 27085322 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 82
Study 23991748 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneXpert MRSA performed after S. aureus identification
Number of subjects: 197
Study 23991748 — intervention group
Group type: COMPARATOR
Intervention: Control group with antibiotic susceptibility testing after MALDI‐TOF MS identification
Number of subjects: 197
Study 23550669 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 1535
Study 23550669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 1535
Study 20610466 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication adherence
Number of subjects: 230
Study 20610466 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' beliefs about hypertension and treatment
Number of subjects: 230
Study 20610466 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance with medical model
Number of subjects: 230
Study 18097174 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR multifocal intraocular lens (IOL)
Number of subjects: 38
Study 18097174 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs (Control)
Number of subjects: 38
Study 18097174 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR multifocal IOL
Number of subjects: 38
Study 16409337 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 27
Study 16409337 — intervention group
Group type: COMPARATOR
Intervention: Mouthpiece
Number of subjects: 27
Study 16409337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both facemask and mouthpiece
Number of subjects: 27
Study 12525508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) for CNS2 and TLP+ patients
Number of subjects: 2021
Study 12525508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) and cranial irradiation (18 Gy) for CNS3 patients
Number of subjects: 2021
Study 12525508 — intervention group
Group type: EXPERIMENTAL
Intervention: TLP+ status
Number of subjects: 2021
Study 12525508 — intervention group
Group type: COMPARATOR
Intervention: CNS1 status
Number of subjects: 2021
Study 12525508 — intervention group
Group type: COMPARATOR
Intervention: CNS2 status
Number of subjects: 2021
Study 12525508 — intervention group
Group type: COMPARATOR
Intervention: CNS3 status
Number of subjects: 2021
Study 12525508 — intervention group
Group type: COMPARATOR
Intervention: CNS1
Number of subjects: 2021
Study 12525508 — intervention group
Group type: COMPARATOR
Intervention: CNS2
Number of subjects: 2021
Study 10731270 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 120
Study 10731270 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 120
Study 8857989 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (15 mmol/L) in the cardioplegic solution (group 1)
Number of subjects: 50
Study 8857989 — intervention group
Group type: COMPARATOR
Intervention: No magnesium sulfate in the cardioplegic solution (group 2)
Number of subjects: 50
Study 1320540 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (10-200 mg)
Number of subjects: 7
Study 1320540 — intervention group
Group type: COMPARATOR
Intervention: Exogenous infusion of synthetic human atrial natriuretic peptide (45-90 micrograms)
Number of subjects: 7
Study 6407290 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen
Number of subjects: 28
Study 6407290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intal
Number of subjects: 28
Study 6407290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Zaditen and Intal
Number of subjects: 28
Study 6407290 — intervention group
Group type: COMPARATOR
Intervention: Zaditen or Intal
Number of subjects: 28